Loading...
•
Dec 31, 2024
Aquestive Q4 2024 Earnings Report
Aquestive reported a decline in revenue and increased net loss in Q4 2024, mainly due to higher expenses and reduced royalty revenues.
Key Takeaways
Aquestive Therapeutics posted a revenue decline of 10% in Q4 2024, with total revenue at $11.9 million. The company reported a net loss of $17.1 million due to increased R&D and SG&A expenses. Non-GAAP adjusted EBITDA loss widened to $11.0 million. The company continued its regulatory progress on Anaphylm and Libervant, while manufacturing and supply revenues also declined.
Total revenue declined 10% YoY to $11.9 million.
Net loss widened to $17.1 million, from $8.1 million a year ago.
R&D expenses increased to $4.9 million due to Anaphylm development.
Non-GAAP adjusted EBITDA loss expanded to $11.0 million.
Aquestive
Aquestive
Aquestive Revenue by Segment
Revenue by Segment
Manufacture and Supply Revenue
CapyFin.com Forward Guidance
Aquestive expects FY 2025 revenue between $47M and $56M, with continued pre-commercial spending on Anaphylm.
Positive Outlook
- Anaphylm NDA submission process initiated.
- Potential FDA approval and launch in Q1 2026.
- Strong cash position of $93M including ATM proceeds.
- Growing demand for Libervant in targeted age group.
- New clinical trials for AQST-108 set for Q2 2025.
Challenges Ahead
- Revenue expected to decline compared to FY 2024.
- Higher SG&A and R&D expenses impacting profitability.
- Increased legal expenses related to FDA appeal for Libervant.
- Expected Suboxone revenue erosion.
- Potential advisory committee delay for Anaphylm approval.